Johnson & Johnson COVID-19 vaccine reportedly 85 per cent effective against severe illness

Another key player in the growing number of available COVID-19 vaccines has released some efficacy data for their vaccine candidate.

American pharmaceutical company Johnson & Johnson’s COVID-19 vaccine, which is notable for only requiring a single dose and a much easier method of storage than its current competitors, is apparently a reported 85 per cent effective against severe illness, and 66 per cent effective against moderate-to-severe illness.

JUST IN: Topline interim data analysis from our Phase 3 ENSEMBLE clinical trial for our investigational single-dose #COVID19 vaccine candidate announced: https://t.co/0IYaigbYvV pic.twitter.com/e1zIJr7qSQ

— Johnson & Johnson (@JNJNews) January 29, 2021

Those numbers fall short of Canada’s currently utilized vaccines, created by Pfizer-BioNTech and Moderna, which are both a massive 95 per cent effective against severe illness.

However, the trade-off of those two current vaccines is that they required a double dose regimen, with each dose being administered weeks to a month apart for prime efficacy. Additionally, storage is an issue, with Pfizer’s vaccine in particular requiring dramatically cold temperatures.

The Canadian government has already signed on to purchase 10 million doses of Johnson & Johnson’s vaccine, and it is currently pending approval by Health Canada.

Read more about the Johnson & Johnson COVID-19 vaccine here.

Share post

Tags

• coronavirus
• COVID-19
• COVID-19 vaccine
• Hamilton
• HamOnt
• Health
• immunization
• Johnson & Johnson
• Moderna
• pandemic
• Pfizer
• Public Health
• vaccination
• vaccine